UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 20, 2010
RENHUANG
PHARMACEUTICALS, INC.
(Exact
name of Registrant as Specified in its Charter)
|
Nevada
|
|
0-24512
|
|
88-1273503
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
No.
281, Taiping Road, Taiping District
Harbin,
Heilongjiang Province, 150050
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: 86-451-5762-0378
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
(d) On
April 20, 2010, Renhuang Pharmaceuticals, Inc. (the “Company”) appointed Mr.
Changxiong Sun, age 65, as a member of the Board of Directors of the
Company. Mr. Sun will serve as an independent director and the
Chairman of the Nominations Committtee of the Board of
Directors. Since 2005 Mr. Sun has served as a Professor and Doctoral
Tutor at the Management College of Harbin Institute of Technology. Since 2005
Mr. Sun has served as the Executive Director of the Overseas Development and
Layout Association of China Industry. Since 2005 Mr. Sun has served
as the Director of the Heilongjiang Dongbeiya Economy and Technology
Committee. From 2004 to 2005, Mr. Sun served as the Vice Secretary
General of the Harbin Municipal Government Committee. From 1999 to
2004, Mr. Sun served as the Director of the Harbin Finance Management
Department. Mr. Sun has a degree in Management Science and
Engineering from the Harbin Institute of Technology.
The Company has agreed to pay Mr. Sun
an annual fee of RMB 36,000, payable on a monthly basis, for his service on the
Board of Directors and as the Chairman of the Nominations Committee of the Board
of Directors.
On April 20, 2010, Renhuang
Pharmaceuticals, Inc. (the “Company”) appointed Mr. Bingchun Wu, age 73, as a
member of the Board of Directors of the Company. Mr. Wu will serve as
an independent director and the Chairman of the Compensation Committtee of the
Board of Directors. Since 2006 Mr. Wu has served as the Team Leader
of the Chinese Medicine Research Group at the Heilongjiang Province Chinese
Medicine Research Institute. From 2006 to 2007, Mr. Wu served as the
Chief Expert of the Chinese Medicine Group of the Innovation System of
Heilongjiang Province Science and Technology Department. From 2004 to
2006, Mr. Wu served as the Director of the Chinese Pharmacology Research Office
and the Head of Chinese Medicine Resaerch at the Heilongjiang Province Science
and Technology Department. Mr. Wu has a degree in Pharmaceutical
Science from Shenyang Medicine University and a bachelor degree in Financial
Management from Harbin University of Commerce.
The Company has agreed to pay Mr. Wu an
annual fee of RMB 36,000, payable on a monthly basis, for his service on the
Board of Directors and as the Chairman of the Compensation Committee of the
Board of Directors.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
RENHUANG
PHARMACEUTICALS, INC.
|
|
|
|
|
|
Date:
April 20, 2010
|
|
By:
|
|
|
|
|
|
|
|
Shaoming
Li
|
|
|
|
|
|
Chief
Executive Officer
|